Sep 19, 2022 7:05am EDT Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia
Aug 15, 2022 7:05am EDT Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial
Aug 11, 2022 7:05am EDT Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 10, 2022 4:01pm EDT Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference
Aug 04, 2022 7:05am EDT Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022
Jun 01, 2022 7:05am EDT Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia
May 12, 2022 7:05am EDT Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 05, 2022 7:05am EDT Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022
Apr 28, 2022 7:05am EDT Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for Fibromyalgia
Mar 17, 2022 7:05am EDT Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
